enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- FDA decision expected in 2H'2025
- Access the "What This Means" segment here
IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness."
Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval.
The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025.
The "What This Means" segment can be accessed here.
About CVI
Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension).
Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLCNVNO@jtcir.com(908) 824-0775
MEDIA CONTACT:Glenn Silver, FINN PartnersGlenn.Silver@finnpartners.com(973) 818-8198
SOURCE: enVVeno Medical Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Former X CEO Yaccarino takes helm at digital health company eMed
(Reuters) -Linda Yaccarino is taking the top job at eMed Population Health, a tele-health startup that focuses on weight loss and diabetes care, just a month after stepping down as CEO of social media platform X. Yaccarino, an advertising industry veteran, exited Elon Musk's X after two turbulent years during which she tried to revive its reputation among advertisers, who were wary of the platform's content as well as the billionaire's steady stream of controversial posts. Although devoid of any experience in the health sector, she does bring in deep expertise in brand partnerships and digital revenue growth. At NBCUniversal, she modernized the global advertising business over a decade. At X, she helped regain advertiser confidence following turbulence under Musk's ownership. In her first public statement following her appointment, Yaccarino said, "There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before." EMed said on Tuesday it aimed to accelerate growth under Yaccarino's leadership, building on existing initiatives such as its partnership with professional services firm Aon. Miami, Florida-based eMed, which was founded in 2020, provides at-home diagnostics, proctor-led screenings and physician-guided prescribing for patients with obesity and type 2 diabetes through its digital platforms. On the online weight management company's website, eMed claims it can reduce the cost of a weight-loss program by up to 50%. Its obesity program provides instant access to live care with no appointments ever.
Yahoo
37 minutes ago
- Yahoo
Hims & Hers stock slides 5% after second quarter revenue misses forecasts
Hims & Hers Health (HIMS) stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of Wall Street forecasts while maintaining its full-year forecast. The telehealth company posted revenue of $544.8 million in the second quarter, which marked a 73% increase year-over-year but missed analyst estimates for $552 million, according to Bloomberg data. Hims maintained its full-year revenue guidance of $2.3 billion-$2.4 billion. Earnings per share topped forecasts, coming in at $0.17 against expectations for $0.15. The stock had dropped as much as 11% in premarket trade. Hims' slide comes after drugmaker Novo Nordisk (NVO) ended a short-lived partnership between the two companies in June that saw Novo Nordisk allows Hims access to its viral weight-loss drug Wegovy. Novo Nordisk alleged in the announcement that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of "personalization" and are disseminating deceptive marketing that put patient safety at risk." Shares in Novo Nordisk fell more than 21% last month after the drugmaker announced that it was slashing profit forecasts for Wegovy and its diabetes treatment Ozempic. In August 2022, the US Federal Drug Administration (FDA) allowed compounding pharmacies, including those working with telehealth providers like Hims, to copy and distribute semaglutide weight-loss and weight-management drugs due to shortages in brand-name products like Wegovy and Eli Lilly's (LLY) Zepbound after massive consumer demand. The move allowed Hims to market a GLP-1 weight-loss drug itself while the shortage was in place, which it began doing in May 2024, according to the FT. But the FDA ended that order in February, citing that the shortage of brand-name GLP-1s had ended and ordering compounding pharmacies to stop production by April. Coming off the FDA ruling, Hims is trying to diversify its product offerings. Management announced in May in a Q1 shareholder letter that its "vision involves expanding from hundreds of personalized treatments today to potentially thousands." Still, the company's stock has been a big winner relative to GLP-1 leaders like Novo and Eli Lilly this year, rising more than 150% year-to-date against a more than 40% slide for Novo shares. Eli Lilly stock is roughly flat this year. "The momentum we saw through the first half of 2025 is proof that our platform is delivering exactly what millions of people have been waiting for, access to personalized, high-quality care that meets people where they are," CEO Andrew Dudum said during Hims' Q2 earnings call. "From the beginning, we have believed that medicine should be centered on the individual, not the system. We are now seeing the market demanding just that. What we have built is working and it's working at scale." Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Elation Health Announces Major AI Expansion of Clinical-First Platform
Best In KLAS EHR/PM company accelerates roadmap delivery with natively built AI workflow solutions for primary care SAN FRANCISCO, August 05, 2025--(BUSINESS WIRE)--Elation Health, the technology company powering innovation in primary care, today unveiled a significant expansion to its technology platform, with clinical-first AI built natively across all products and now available to customers for no additional cost. With this launch, Elation takes a major step forward in its founding mission to remove every obstacle between clinicians and their patients. The suite of newly embedded AI capabilities accelerate innovation across end-to-end workflows, built natively into the EHR and Billing platform. Designed to support high-value primary care, the expanded platform streamlines critical preventive care workflows, reduces administrative burden, and strengthens the physician-patient relationship, restoring the craft and joy at the heart of medicine. Ranked "Best in KLAS" – with users highlighting clinician experience – in February 2025, Elation continues a "built in" approach to AI development with this launch, with momentum already behind the company's Note Assist, an ambient AI Scribe, and Actions, a task automation feature, which have garnered positive feedback from physicians, nurses, and practice staff. "Our vision hasn't changed since the beginning: we are powered by the radical idea that technology can provide clinicians the freedom to focus on their patients," said Kyna Fong, CEO and co-founder of Elation Health. "What has changed is what's now possible. AI is a tremendous accelerator of that mission, and by including it in Elation, embedded natively across every facet of the practice, we can deliver on that mission faster, more comprehensively, and with greater clinician delight." Elation's approach to AI is rooted in transparency and clinician trust. Every AI-powered feature is clearly identified within the workflow, ensuring users always know when intelligence is at work and remain in control over the outcome. AI-powered features already garnering attention from early users include: Elation Note: A new dynamic documentation canvas purpose-built for AI, enabling flexible, efficient note-taking. Note Assist and Actions work seamlessly within, allowing providers flexibility in how they express themselves while still capturing critical structured data for value-based success. Clinical Insights: Surfaces meaningful, context-aware summaries of patient information — such as medications, labs, and conditions — saving clinicians time from intensively searching through the chart and improving decision-making. Wordsmith: Drafts post-visit communications including referrals, provider letters, and patient letters, using generative AI with customizable tone, style, and structure for maximum efficiency and flexibility. AI-enhanced Clinical Forms: Instantly transforms scanned intake templates into structured digital experiences, personalizing questions, streamlining data collection, and freeing the practice to focus on meaningful patient connection. "This is just the beginning. We're committed to working directly alongside our customers to iterate, refine, and expand Elation," said Phill Tornroth, VP of Engineering at Elation Health. "New features, deeper automation, and enhanced insights will continue to roll out so our primary care clinicians and their staff always have the smartest tools to deliver exceptional care and are ready to meet the future with confidence." To request a demo and learn more about the new AI features and Elation's clinical-first AI approach, please visit here. To join Elation's product developers for a live, interactive webinar exploring how clinical-first AI embedded within the EHR is transforming primary care by reducing burnout, improving care quality, and empowering both clinicians and patients, please register here. About Elation Health Elation Health is the clinical-first AI platform for primary care success. Trusted by over 40,000 clinical users caring for 21 million patients, Elation's EHR and billing solutions combine proven clinical workflows with responsible AI, purpose-built for primary care. The company's clinical-first approach puts patient care at the center, delivering trusted, transparent innovation that saves physicians time and sustains meaningful patient relationships. Elation Health is recognized as Best in KLAS for its commitment to excellence in primary care technology. Learn more at and on LinkedIn. View source version on Contacts media@ 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
